0001640455-21-000021.txt : 20210125
0001640455-21-000021.hdr.sgml : 20210125
20210125173658
ACCESSION NUMBER: 0001640455-21-000021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210122
FILED AS OF DATE: 20210125
DATE AS OF CHANGE: 20210125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cole Hugh M
CENTRAL INDEX KEY: 0001604646
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 21550943
MAIL ADDRESS:
STREET 1: C/O ARIAD PHARMACEUTICALS, INC
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_161161420401615.xml
FORM 4
X0306
4
2021-01-22
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001604646
Cole Hugh M
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Business Officer
Common Stock
2021-01-22
4
M
0
5000
4.40
A
60189
D
Common Stock
2021-01-22
4
M
0
5000
6.55
A
65189
D
Common Stock
2021-01-22
4
S
0
18000
11.95
D
47189
D
Stock Option (Right to Buy)
4.4
2021-01-22
4
M
0
5000
0
D
2029-02-01
Common Stock
5000.0
39500
D
Stock Option (Right to Buy)
6.55
2021-01-22
4
M
0
5000
0
D
2030-02-03
Common Stock
5000.0
55000
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 22, 2020. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 18,000 shares sold in the price range of $11.66 to $12.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option will vest quarterly in 16 equal installments following January 1, 2019.
The option will vest quarterly in 16 equal installments following January 1, 2020.
/s/ Caroline Gammill, Attorney-in-fact
2021-01-25